news
Treat-to-target colitis care puts deep gut healing ahead of symptom relief
A Phase 4 trial presented in Barcelona showed that over 50% of patients with moderate to severe ulcerative colitis achieved endoscopic and histological healing on vedolizumab. The strategy pushes gut care beyond masking daily discomfort to actual tissue recovery. It shifts clinical standards from feeling fine to measurable mucosal repair.
A Phase 4 trial presented in Barcelona showed that over 50% of patients with moderate to severe ulcerative colitis achieved endoscopic and histological healing on vedolizumab. The strategy pushes gut care beyond masking daily discomfort to actual tissue recovery. It shifts clinical standards from feeling fine to measurable mucosal repair.
The architecture take
For years, I assumed settling an upset stomach meant the fire was out. If cramping stopped and bathroom trips normalized, I called it a win and moved on. This Barcelona trial on vedolizumab shows why that assumption was sloppy. Over 50 percent of ulcerative colitis patients on this gut-selective integrin inhibitor reached microscopic tissue healing, not just day-to-day symptom quiet. That gap between feeling okay and having genuinely healed mucosa is where long-term relapses hide. When rogue white blood cells don't invade the intestinal lining, the gut wall actually repairs its barrier. Most chronic gut protocols still treat absence of pain as the finish line (often because routine colonoscopies are unpleasant to schedule). I changed my mind about this after watching friends bounce through endless flare cycles. Quiet matters. If systemic inflammation is quietly simmering under the surface, the nervous system doesn't get a true ceasefire. Demanding objective biopsy proof turns gut recovery into real biology.